Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising efficacy in NSCLC, with a strong clinical pipeline and upcoming catalysts. Commercial ramp of lifileucel is underway, with 2025 sales at $220M and gross margins improving to 50%, but operational and adoption hurdles persist.
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma.
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a precarious cash runway, and intense competition, but real-world efficacy and expanding treatment center networks support cautious optimism. Key 2026–2027 catalysts include potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions hinging on successful clinical and regulatory milestones.
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100.
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then; ex-U.S. partnerships are a potential solution.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.
